Physician profile
Rae E Ringenberg
NPI 1477500494
$6,001.65
in general payments reported to CMS, 2019-2025
16 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $614 · 2021: $389 · 2022: $589 · 2023: $1,203 · 2024: $990 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,469 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,468.86 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,740.70 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $677.59 | 2019-2025 | Ozempic |
| Glaxosmithkline, LLC. | $634.84 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $485.00 | 2019-2025 | Repatha |
| Lilly USA, LLC | $440.39 | 2023-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.76 | 2019-2023 | Jardiance |
| Abbvie INC. | $351.20 | 2023-2025 | Qulipta, Ubrelvy |
| Amarin Pharma, INC. | $255.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $223.40 | 2019-2020 | |
| Abbott Laboratories | $211.05 | 2023-2024 | Infinity, Freestyle Libre 2, Freestyle Libre 3 |
| Genentech USA, INC. | $125.17 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Merck Sharp & Dohme LLC | $117.44 | 2025 | Capvaxive |
| Novartis Pharmaceuticals Corporation | $111.31 | 2019 | |
| Horizon Therapeutics Plc | $87.11 | 2023 | Krystexxa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $60.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rae Ringenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.